哌喹化合物为白色至淡黄色的结晶性粉末,无臭,味微苦,化学名为4,4' - (1,3-丙二基二-4,1-哌嗪二基)双(7-氯喹啉);临床主要用于疟疾症状的抑制性预防,也用于疟疾的治疗,并试用于矽肺的防治。
哌喹合成新工艺的探讨_药学论文 关键词】哌喹;抗疟药;合成;新工艺 [gap=715]Key words】Piperaquine; Antimalaria drug; Synthesis;Process
基于494个网页-相关网页
【摘要】: 目的:评价比较青蒿素-哌喹(Artequick)和双氢青蒿素-磷酸哌喹(Artekin)治疗无并发症恶性疟的疗效和安全性。方法:收治无并发症恶性疟患者共103例,随机分组。
基于16个网页-相关网页
... 盐酸班布特罗Bambuterol Hydrochloride 哌喹Policresulen Impurity A 佐尼沙胺Zonisamide ...
基于1个网页-相关网页
磷酸哌喹 Piperaquine Phosphate ; PiperaquinephosphateCAS ; Piperaqu ; Eurartesim
三哌喹 Tripiperaquine
哌喹齐尔 Piquizil
哌喹新 Peraquinsin
磷酸哌喹片 Piperaquine Phosphate Tablets
双氢青蒿素哌喹片 Dihydroartemisinin and Piperaquine Phosphate Tablets ; Dihydroartemisinin and Piperaquine Phosphate ; Dihydroartemisinin and Piperaq
磷酸羟基哌喹 hydroxypiperquine phosphate ; HPQP
及磷酸羟基哌喹 Hydroxypiperaquine phosphdined ; Hydroxypiperaquine phosphingested ; Hydroxypiperaquine phosphgot ; Hydroxypiperaquine phosphconsumed
RESULTS: Except for the absence of resistance to mefloquine and quinine, the resistance rate of the parasite to chloroquine, amodiaquine and piperaquine was 84 6%, 86 1% and 38 0% respectively.
结果:甲氟喹和奎宁分别测定36例和33例,未发现抗性病例。 氯喹、氨酚喹和哌喹抗性率分别为84.6%、86.1%和38.0%。
参考来源 - 我国恶性疟原虫对抗疟药敏感性的现状·2,447,543篇论文数据,部分数据来源于NoteExpress
目的 观察双氢青蒿素哌喹复方片对缅甸无并发症恶性疟的疗效。
Objective To observe the therapeutic efficacy of compound dihydroartemisinin-piperaquine for treatment of uncomplicated falciparum malaria in Myanmar.
目的:探讨双氢青蒿素哌喹片在柬埔寨马德望省治疗无并发症恶性疟的有效性和安全性。
AIM: To explore the effect and safety of dihydroartemisinin piperaquine(DP) phosphate tablet in treatment of uncomplicated falciparum malaria in battambang of Combodia.
世卫组织现已将双氢青蒿素加上哌喹作为第五个青蒿素为基础的联合疗法,添加到以往建议的药品清单中。
WHO has now added a fifth ACT - dihydroartemisinin plus piperaquine - to the previous list of recommended medicines.
应用推荐